



VIEWS AND REVIEWS

1 Are we ready to eliminate the transfer of fresh embryos in in vitro fertilization?



K. T. Barnhart
Philadelphia, Pennsylvania

The rationale to freeze all embryos to avoid transfer into a supraphysiologic environment to improve safety and efficacy is compelling, but not yet proven. How do we decide?

3 Clinical rationale for cryopreservation of entire embryo cohorts in lieu of fresh transfer



B. S. Shapiro, S. T. Daneshmand, F. C. Garner, M. Aguirre, and C. Hudson
Las Vegas, Nevada

Frozen embryo transfer is now competitive with fresh transfer and may be superior in some cases. Numerous factors should be considered when deciding between them.

10 Why we should transfer frozen instead of fresh embryos: the translational rationale



R. Weinerman and M. Mainigi
Philadelphia, Pennsylvania

Frozen transfer allows embryos to implant and develop in a more physiologic environment. This review summarizes the research on the effect of the superovulated environment on implantation and embryo development.

19 Cryopreservation of human embryos and its contribution to in vitro fertilization success rates



K. M. Wong, S. Mastenbroek, and S. Repping
Amsterdam, the Netherlands

The success rates after frozen-thawed embryo transfer are nearing those of fresh transfer in assisted reproductive technology cycles. Randomized controlled trials should determine whether fresh transfers should be abandoned.

27 Cryopreservation and delayed embryo transfer—assisted reproductive technology registry and reporting implications



K. J. Doody
Bedford, Texas

Some assisted reproductive technology cycles designated as “embryo banking” have been excluded from public reports. The Society for Assisted Reproductive Technology and the Centers for Disease Control and Prevention have collaborated to recapitulate these cycles.

INKLINGS

32 Contraception—when did something so right go so wrong?



M. I. Cedars
San Francisco, California

Fertility and Sterility® (ISSN 0015-0282) is a registered trademark of the American Society for Reproductive Medicine and is published monthly in two volumes by Elsevier Inc., 360 Park Avenue South, New York, NY 10010-1710. Periodicals postage paid at New York, NY and at additional mailing offices. Membership dues to the American Society for Reproductive Medicine include \$50.00 for *Fertility and Sterility*®. Publication of an advertisement or other product mentioned in *Fertility and Sterility* should not be construed as an endorsement of the product or the manufacturer's claim. Statements and opinions expressed in articles and communications herein are those of the authors and not necessarily those of the editors, publisher, or the American Society for Reproductive Medicine or any organizations endorsing this journal. **Subscriptions:** Personal rates: US\$401.00; all other countries US\$643.00. Students: All countries US\$163.00. Prices include postage and are subject to change without notice. Any enquiry relating to subscriptions should be sent to: **The Americas:** Elsevier Health Sciences Division, Subscription Customer Service, 3251 Riverport Lane, Maryland Heights, MO 63043; Tel: (800) 654-2452 (U.S. and Canada), (314) 447-8871 (outside U.S. and Canada); Fax: (314) 447-8029; E-mail: journalscustomerservice-usa@elsevier.com (for print support); journalsonline-support-usa@elsevier.com (for online support). **Japan:** Elsevier Inc., Customer Support Department, 9-15 Higashi-Azabu 1-chome, Minato-ku, Tokyo 106-0044, Japan; Tel: (+81) 3 5561-5033; Fax: (+81) 3 5561-5047; e-mail: info@elsevier.co.jp. **Asia Pacific (excluding Japan):** Elsevier Inc. (Singapore) Pte Ltd., No. 1 Temasek Avenue, 17-01 Millenia Tower, Singapore 039192; Tel: (+65) 434-3727; Fax: (+65) 337-2230; e-mail: asiainfo@elsevier.com.sg. **Latin America:** Elsevier Inc., Rua Sete de Setembro 111/16 Andar, 20050-002 Centro, Rio de Janeiro - RJ, Brazil; Tel: (+55) (21) 3970 9300; Fax: (+55) (21) 2507 1991; e-mail: rsola.info@elsevier.com.br. **South America:** for orders, claims, and help desk information, please contact the Regional Sales Office in Florida as listed above. **Rest of World:** Elsevier Inc., Customer Service Department, P.O. Box 211, 1001 AE Amsterdam, the Netherlands; Tel: (+31) 20-485-3757; Fax: (+31) 20-485-3432; e-mail: nlinfo-f@elsevier.nl.

POSTMASTER: Send address changes to *Fertility and Sterility*®, Elsevier Health Sciences Division, Subscription Customer Service, 3251 Riverport Lane, Maryland Heights, MO 63043.



34 Has noninvasive fetal trisomy testing (NIFTY) rung the death knell for other forms of prenatal testing?



F. R. Parikh, M. Panpalia, and M. Khandeparkar
Mumbai, India

CONCEPTIONS

36 Preterm births, multiples, and fertility treatment: recommendations for changes to policy and clinical practices



J. Johnston, M. K. Gusmano, and P. Patrizio
Garrison, New York; and New Haven, Connecticut

40 Ethics of uterus transplantation with live donors



M. Olausson, L. Johannesson, D. Brattgård, C. Diaz-Garcia, C. Lundmark, K. Groth, J. Marcickiewicz, A. Enskog, R. Akouri, A. Tzakis, X. Rogiers, P. O. Janson, and M. Brännström
Göteborg, Sweden; Valencia, Spain; Cleveland, Ohio; and Ghent, Belgium

ORIGINAL ARTICLES

ANDROLOGY

44 Urinary metabolome identifies signatures of oligozoospermic infertile men



J. Zhang, Z. Huang, M. Chen, Y. Xia, F. L. Martin, W. Hang, and H. Shen
Xiamen and Nanjing, People's Republic of China; and Lancaster, United Kingdom



The urinary metabolome could differentiate oligozoospermic infertile men from fertile men. The disrupted metabolic pathways reflected fertility reduction that may be tightly associated with energy consumption and antioxidant defenses in spermatogenesis.

54 Raman spectroscopy as an ex vivo noninvasive approach to distinguish complete and incomplete spermatogenesis within human seminiferous tubules



Y. Liu, Y. Zhu, L. Di, E. C. Osterberg, F. Liu, L. He, H. Hu, Y. Huang, P. S. Li, and Z. Li
Shanghai, People's Republic of China; and New York, New York



Raman spectroscopy may noninvasively identify different maturational stages of spermatogenesis in ex vivo human seminiferous tubules.

61 Decreased expression of SAM68 in human testes with spermatogenic defects



L.-J. Li, F.-B. Zhang, S.-Y. Liu, Y.-H. Tian, F. Le, H.-Y. Lou, H.-F. Huang, and F. Jin
Zhejiang, People's Republic of China



Deficient expression of SAM68 might be one of the factors involved in the mechanism underlying spermatogenic defects. These results may offer new perspectives on the molecular basis of abnormal spermatogenesis.

68 Nomograms for predicting changes in semen parameters in infertile men after varicocele repair



M. K. Samplaski, C. Yu, M. W. Kattan, K. C. Lo, E. D. Grober, A. Zini, S. Lau, and K. A. Jarvi
Toronto, Ontario and Montreal, Quebec, Canada; and Cleveland, Ohio

We formulated nomograms to predict improvements in semen parameters (total motile count, sperm concentration, motility, and morphology) after varicocele repair using multivariable linear regression.

ASSISTED REPRODUCTION

75 Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment?



J. Ren, A. Sha, D. Han, P. Li, J. Geng, and C. Ma
Fujian, People's Republic of China

In a comparison of the regular long protocol with a prolonged protocol with 28-days' down-regulation, a significantly higher live-birth rate (55.56% vs. 45.73%) was observed with the prolonged protocol.

Download English Version:

<https://daneshyari.com/en/article/6180123>

Download Persian Version:

<https://daneshyari.com/article/6180123>

[Daneshyari.com](https://daneshyari.com)